<DOC>
	<DOCNO>NCT01147848</DOCNO>
	<brief_summary>The purpose study compare efficacy safety fluticasone furoate/vilanterol ( GW642444 ) inhalation powder administer daily fluticasone propionate/salmeterol administer twice daily adolescent adult subject 12 year age old persistent bronchial asthma 24-week period .</brief_summary>
	<brief_title>HZA113091 Efficacy Safety Fluticasone Furoate/Vilanterol ( GW642444 ) Adults Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Clinical diagnosis asthma Reversibility least 12 % least 200mLs within 1040 minute follow 24 inhalation albuterol FEV1 4085 % predict normal Currently use inhale corticosteroid therapy History lifethreatening asthma within previous 5 year ( require intubation and/or associate hypercapnoea , respiratory arrest hypoxic seizure ) Respiratory infection oral candidiasis Asthma exacerbation require oral corticosteroid result overnight hospitalisation require additional asthma treatment Uncontrolled disease clinical abnormality Allergies Taking another investigational medication prohibit medication Night shift worker Current smoker subject smoke history least 10 pack year</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Salmeterol</keyword>
	<keyword>fluticasone furoate</keyword>
	<keyword>Vilanterol</keyword>
	<keyword>fluticasone propionate</keyword>
	<keyword>GW642444</keyword>
</DOC>